CAR T
Showing of 12 results
Multiple Myeloma Patients at UH Seidman Cancer Center Have New Immunotherapy Option
BAFF CAR T has important advantage for these patients - Innovations in Cancer | July 2024
UH Seidman Researchers Slash Time Needed to Produce CAR T-Cells
Quicker process will get needed therapy to cancer patients who don’t have time to wait - Innovations in Cancer | Fall 2022
Novel Strategy to Improve CAR T-cell Efficacy in Non-Hodgkin Lymphoma Revealed in Preclinical Studies
University Hospitals Seidman Cancer Center researchers part of team finding blocking a single receptor may combat T cell dysfunction associated with poor response to therapy - Innovations in Cancer | Summer 2022
Team Led by UH Seidman Cancer Center Researcher Develops and Validates Three-in-One CAR T Therapy
Approach detailed in the journal Nature Communications shows therapeutic potential of BAFF CAR T for treating multiple B cell cancers, using mouse models with high effectiveness and minimum side effects - Innovations in Cancer | Winter 2022
Anti-CD19 CAR T-Cells Produced Locally at UH Seidman Cancer Center Induce High Remission Rates in B-cell Malignancies, Study Finds
Clinical trials published in Nature Communications detail advantages of local approach - Innovations in Cancer | Fall 2021
Multiple Myeloma Patients at UH Seidman Cancer Center First in Ohio to Receive New CAR T-Cell Therapy
Patients also have access to promising clinical trial of vactosertib and pomalidomide - Innovations in Cancer | Summer 2021
New Immunotherapy Center at UH Seidman Cancer Center Sets the Stage for Solutions
Center offers dozens of clinical trials, including soon a rare all-human protein CAR T trial for patients with certain hematologic malignancies - Innovations in Cancer | Winter 2021
More Specific Approach to CAR T Cell Therapy Shows Promise for B Cell Cancers
Investigational New Drug (IND) authorization is under way - Innovations in Cancer | Fall 2020